Capitol Hill briefing addresses research agenda to end AIDS epidemic

In a guest blog post on the Center for Global Health Policy's "Science Speaks," Chris Collins, vice president and director of public policy at amfAR: The Foundation for AIDS Research, and Mitchell Warren, executive director of AVAC: Global Advocacy for HIV Prevention, summarize a Capitol Hill briefing "on the research agenda for beginning to end the AIDS epidemic" that took place Wednesday. "[R]esearchers, policymakers, and advocates joined our organizations and the Congressional HIV/AIDS Caucus" at the briefing to discuss "the research agenda needed to bring the epidemic to a close, with special focus on" combination interventions for treatment and prevention; "progress on vaccine and cure research"; and the importance of HIV testing, they write. Collins and Warren conclude, "We need to finance the response, make strategic choices about what to bring to scale (and what not to) and stop discriminating against high-risk populations. Whether you're a researcher, policymaker or advocate, new scientific developments are how we end the epidemic" (5/24).


    http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

    Comments

    The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
    Post a new comment
    Post

    While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

    Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

    Please do not ask questions that use sensitive or confidential information.

    Read the full Terms & Conditions.

    You might also like...
    Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy